Hunter, Jill E., Campbell, Amy E., Hannaway, Nicola L., Kerridge, Scott, Luli, Saimir, Butterworth, Jacqueline A., Sellier, Helene, Mukherjee, Reshmi, Dhillon, Nikita, Sudhindar, Praveen D., and others. (2022) Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathway. Biochemical Journal, 479 (19). pp. 2063-2086. ISSN 0264-6021. (doi:10.1042/BCJ20220102) (KAR id:107958)
PDF
Publisher pdf
Language: English
This work is licensed under a Creative Commons Attribution 4.0 International License.
|
|
Download this file (PDF/15MB) |
Preview |
Request a format suitable for use with assistive technology e.g. a screenreader | |
Official URL: https://doi.org/10.1042/BCJ20220102 |
Abstract
Previously, we discovered that deletion of c-Rel in the Eµ-Myc mouse model of lymphoma results in earlier onset of disease, a finding that contrasted with the expected function of this NF-κB subunit in B-cell malignancies. Here we report that Eµ-Myc/cRel−/− cells have an unexpected and major defect in the CHK1 pathway. Total and phospho proteomic analysis revealed that Eµ-Myc/cRel−/− lymphomas highly resemble wild-type (WT) Eµ-Myc lymphomas treated with an acute dose of the CHK1 inhibitor (CHK1i) CCT244747. Further analysis demonstrated that this is a consequence of Eµ-Myc/cRel−/− lymphomas having lost expression of CHK1 protein itself, an effect that also results in resistance to CCT244747 treatment in vivo. Similar down-regulation of CHK1 protein levels was also seen in CHK1i resistant U2OS osteosarcoma and Huh7 hepatocellular carcinoma cells. Further investigation revealed that the deubiquitinase USP1 regulates CHK1 proteolytic degradation and that its down-regulation in our model systems is responsible, at least in part, for these effects. We demonstrate that treating WT Eµ-Myc lymphoma cells with the USP1 inhibitor ML323 was highly effective at reducing tumour burden in vivo. Targeting USP1 activity may thus be an alternative therapeutic strategy in MYC-driven tumours.
Item Type: | Article |
---|---|
DOI/Identification number: | 10.1042/BCJ20220102 |
Uncontrolled keywords: | CHK1, CREl, deubiquitinase, DNA replication stress, inhibitor resistance, nuclear factor κB |
Subjects: |
R Medicine R Medicine > RM Therapeutics. Pharmacology |
Divisions: | Divisions > Division of Natural Sciences > Biosciences |
Funders: |
Cancer Research UK (https://ror.org/054225q67)
University of Kent (https://ror.org/00xkeyj56) |
Depositing User: | Michelle Garrett |
Date Deposited: | 27 Nov 2024 21:12 UTC |
Last Modified: | 02 Dec 2024 13:21 UTC |
Resource URI: | https://kar.kent.ac.uk/id/eprint/107958 (The current URI for this page, for reference purposes) |
- Link to SensusAccess
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):